Qinlock is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, in adults with advanced disease who have already been treated with three or more medicines of the ‘kinase inhibitor’ class, including a medicine called imatinib. GIST is rare, and Qinlock was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 October 2017. Qinlock contains the active substance ripretinib.
Therapeutic Indication
### Therapeutic indication Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Therapeutic Area (MeSH)
N/AATC Code
L01
ATC Item
抗肿瘤药
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| ripretinib | N/A | 瑞派替尼 |
EMA Name
Qinlock
Medicine Name
Qinlock
Aliases
N/ANo risk management plan link.
